The global biopharmaceutical contract manufacturing market is anticipated to experience significant growth from 2024 to 2032. This market's expansion is driven by continuous technological innovations, increased research and development (R&D) investments, and strategic collaborations among key
KBI Biopharma, a prominent contract development and manufacturing organization (CDMO), encountered a critical issue during a GMP (Good Manufacturing Practice) production run. An unexpected pink discoloration appeared in the cell culture media, a crucial component for biologic drug production. The
The resignation of Mr. Zhou Honghao, an independent non-executive director from Genor Biopharma Holdings Limited, has sparked considerable debate and concern among investors and market watchers. With the effective date of the resignation set for September 18, 2024, there are critical questions to
Ireland has long established itself as a significant player in the global biopharmaceutical industry, boasting a thriving ecosystem supported by robust regulatory and governmental frameworks. With the recent appointment of Shane Ryan as the new president of the Irish Pharmaceutical Healthcare
The biotech sector is brimming with opportunities that extend far beyond the much-talked-about GLP-1 weight-loss drugs, which have garnered significant attention following the 2024 European Association for the Study of Diabetes (EASD) meeting. While GLP-1 treatments, led by giants like Eli Lilly
Theratechnologies, a Quebec-based biopharmaceutical company, is currently navigating challenging waters as it faces potential disruptions in the supply of its crucial HIV medication, Egrifta SV. This drug is widely used to reduce excess abdominal fat in HIV patients suffering from lipodystrophy.
